Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder.
BACKGROUND
Tumor markers have an increasing significance in the diagnosis and evaluation of tumor, but their role in gallbladder cancer has not been established. The present study was undertaken to determine the utility of serological markers in carcinoma of the gallbladder (CaGB).


METHODS
This study was carried out in 55 cases and 8 healthy controls presenting to a single surgical unit of the University Hospital, Varanasi, India. CA242, CA19-9, CA15-3 and CA125 were assayed preoperatively in serum of patients with carcinoma of the gallbladder (39), cholelithiasis (16) and healthy controls (8) using ELISA technique.


RESULTS
Mean concentration of all tumor markers was significantly raised in carcinoma of the gallbladder when compared with cholelithiasis. CA 242 was 12.10 vs 42.19 u/ ml, CA19-9 was 211.27 vs 86.06 uml, CA 15-3 was 71.42 vs 1.93u/ml and CA125 was 253.61 vs 65.5 u/ml <0.05). Sensitivity and specificity were calculated at various cut off points. Significant changes in CAl9-9 and CA242 occurred with advanced stage (p <0.05) and grade of tumor (p<0.00 1). When two tumor markers were combined, like CA242 and CA125, sensitivity and specificity improved to 87.5% and 85.7% respectively. Diagnostic accuracy is highest with a combination of CA 19-9 and CA 125 (80.65%). However, combination of tumor markers did not improve any further sensitivity or specificity of markers.


CONCLUSIONS
Assay of CA242, CA15-3, CA19-9 and CA 125 are fairly good markers for discriminating patients of carcinoma of the gallbladder from cholelithiasis. CA242 and CA125 when used together achieved best sensitivity and specificity. Serum markers seem to be less sensitive when used individually in carcinoma of the gallbladder but may prove useful in combination.
Shukla
Vijay K
VK
Department of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221 005. vkshuklabhu@gmail.com
Gurubachan
Sharma
Deborshi
D
Dixit
V K
VK
Usha
D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D016022:Case-Control Studies; D005706:Gallbladder Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D006801:Humans; D018396:Mucin-1; D012372:ROC Curve; D012680:Sensitivity and Specificity
D015295:Antigens, Tumor-Associated, Carbohydrate; C074601:CA 242 antigen; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D018396:Mucin-1